Conference Scene

The Cambridge Healthtech Institute’s (CHI) 18th International Molecular Medicine Tri-Conference 2011 brought together all the key stakeholders in the stem cells marketplace including academic researchers, researchers from biotechnology companies, as well as business leaders involved in various aspects of the regenerative medicine space. The focus of the stem cells track, of this 12-track conference, was on the translation of basic stem cell discoveries into preclinical and clinical milestones. Many presentations focused on the production of induced pluripotent stem cells from various patient populations and the potential utilization of induced pluripotent stem cells in the future for cellular therapy. In this article, I provide a snapshot of this conference and highlight selected presentations, giving the overall direction that the stem cell field is taking.